
RealRate

PHARMACEUTICAL 2019



ChemoCentryx Inc. Rank 136 of 371



RealRate

PHARMACEUTICAL 2019



ChemoCentryx Inc. Rank 136 of 371

The relative strengths and weaknesses of ChemoCentryx Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ChemoCentryx Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 113% points. The greatest weakness of ChemoCentryx Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is -78%, being 253% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	181,384
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	64,396
Liabilities, Non-Current	20,076
Other Assets	390
Other Compr. Net Income	-79
Other Expenses	0
Other Liabilities	84,100
Other Net Income	2,304
Property and Equipment	1,536
Research and Development	62,736
Revenues	42,875
Selling, General and Administrative Expense	20,409

Output Variable	Value in 1000 USD
Assets	183,310
Liabilities	168,572
Expenses	83,145
Stockholders Equity	14,738
Net Income	-37,966
Comprehensive Net Income	-38,006
Economic Capital Ratio	-78%